Rising India Inc. Highlights Shareholder Conference Call Regarding Cannabis Pharmaceutical Research and Development Merger
Marketwired MarketwiredFebruary 27, 2017
NEW YORK, NY--(Marketwired - Feb 27, 2017) - Rising India Inc. ( OTC : RSII ) has received several requests from shareholders for a recap to the Company's Shareholder Conference call which featured detailed information about the incoming merger company, Rising Biosciences, Inc.
Rising BioSciences, Inc. will be a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. Aside from cancer treatment and pain management, some of the uses for medical marijuana include treatment of conditions such as seizure disorders, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, glaucoma and Crohn's disease.
Rising Biosciences is comprised of a team of chemists, physicians, pharmacists and medical marijuana industry veterans for the development of products in a clinical lab environment. Operations will focus on creating product that can be metabolized by the body more efficiently, and with delivery methods more acceptable than smoking, tinctures and oils available on the market today.
Procedures will include consistency in terms of quality and true dosage measures of CBD and/or THC delivery through each product the company develops and manufactures.
To date, the industry suffers from a lack of overall quality control of product, including accurate dosage. Rising Biosciences intends to be an industry standout by using policies and procedures set forth by the compounding pharmaceutical industry while monitoring safety and quality throughout.
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindia
All my posts are based on my opinion. Do not buy, sell, trade any stock based on my posts. Do your own due diligence before making any transaction.
